Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.
This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.
Inclusion Criteria:
Exclusion Criteria:
Evansville, Kentucky 47713, United States
CABA, 1426, Argentina
CABA, C1119ACN, Argentina
CABA, C1120AAC, Argentina
Capital Federal, C1425DES, Argentina
CiudadAutonoma de Buenos Aires, C1419AHL, Argentina
Mar Del Plata Buenos Aires, B7600DIA, Argentina
Meadobank, 4131, Australia
North York, Ontario M3M 3E5, Canada
Chuangchun, 130012, China
Bogotá D.C., Colombia
Olomouc-Lazce, 779 00, Czechia
Praha 10, Prague, 100 34, Czechia
Kiel-Kronshagen, 24119, Germany
Saint Peterburg, 195112, Russia
St.Рetersburg, 198035, Russia
Thymen, 625023, Russia
Gwangjin-gu, 110-744, South Korea
Palma deMallorca, 07010, Spain
Kaohsiung Hsien, 83301, Taiwan
Kweishan Shiang, 333, Taiwan
Tainan County, Taiwan
Donetck, 83045, Ukraine
Zaporizhia, 69001, Ukraine
Suffolk, IP33 2QZ, United Kingdom
West Sussex, RH10 7DX, United Kingdom